Pre-clinical Toxicology Summary of Ilizomab

Introduction

This summary provides an overview of the preclinical toxicology evaluation of Ilizomab, a monoclonal antibody targeting [specific immune pathway], conducted in rodent and non-human primate models to assess its safety, pharmacokinetics, and potential toxicity profile.

Study Design

- Species: Rats and Cynomolgus monkeys
- **Duration:** 28-day and 90-day repeat-dose studies
- Doses: Low (1 mg/kg), Medium (5 mg/kg), High (15 mg/kg)
- Endpoints Assessed:
 - Clinical observations (body weight, food consumption, clinical signs)
 - o Hematology, serum chemistry, and cytokine profiling
 - Organ pathology (gross and histopathology)

Key Findings

General Tolerability:

- Ilizomab was well tolerated at doses up to 15 mg/kg in both species
- No treatment-related mortality observed

Hematological Effects:

 Mild, dose-dependent decreases in lymphocyte counts at high doses, reversible after treatment cessation

• Liver and Renal Toxicity:

No significant liver enzyme elevations or renal dysfunction markers detected

Cytokine Modulation:

 Dose-dependent reduction in inflammatory cytokines (IL-6, TNF-α), consistent with proposed mechanism of action

• Immunogenicity:

Low anti-drug antibody formation in non-human primates

• Observed Side Effects:

- o Mild to moderate **fatigue** was noted in some animals, resolving post-dosing
- Nausea observed at higher doses but did not impact overall health outcomes
- Syncope-like episodes recorded in isolated cases at 15 mg/kg, transient and not dose-limiting

Conclusion

Ilizomab demonstrated a favorable safety profile in preclinical models, with no dose-limiting toxicities identified. Mild fatigue, nausea, and rare instances of syncope were observed but were not associated with long-term adverse effects. The findings support further clinical development in SLE patients, with careful monitoring of hematological parameters and potential side effects during clinical trials.